Adverse event profiles of hypomagnesemia caused by proton pump inhibitors using the Japanese Adverse Drug Event Report (JADER) Database

被引:3
|
作者
Yamashiro, K. [1 ]
Hosomi, K. [2 ]
Yokoyama, S. [2 ]
Ogata, F. [1 ]
Nakamura, T. [1 ]
Kawasaki, N. [1 ]
机构
[1] Kindai Univ, Fac Pharm, Lab Publ Hlth, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan
[2] Kindai Univ, Fac Pharm, Div Drug Informat, Osaka, Japan
来源
PHARMAZIE | 2022年 / 77卷 / 7-9期
关键词
MAGNESIUM; RANITIDINE; OMEPRAZOLE; BIAS;
D O I
10.1691/ph.2022.2416
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Proton pump inhibitors (PPIs) are commonly used for the prevention or treatment of gastric ulcers, but they can induce hypomagnesemia. Little is known about the onset duration and risk factors related to patient charac-teristics of this adverse event in Japanese patients. Therefore, we analyzed the time-to-onset of PPI-induced hypomagnesemia and evaluated the association between hypomagnesemia and PPIs using the Japanese Adverse Drug Event Report (JADER) database. We analyzed hypomagnesemia cases between 2004 and 2021. The time-to-onset analysis was performed using the Weibull distribution, and the adjusted reporting odds ratio (aROR) or 95% confidence interval (95% CI) was calculated using a multiple logistic regression analysis. The analysis database comprised 236,525 cases, with 188 cases associated with hypomagnesemia. The median onset duration (interquartile range) of PPI-induced hypomagnesemia was 99.0 (51.8-285.5) days, which is considered the random failure type. The multiple logistic regression analysis revealed that hypomagnesemia is significantly associated with male sex (aROR, 95% CI: 1.66, 1.23-2.25), age < 60 (1.59, 1.14-2.21), estimated body-mass index (eBMI) (0.94, 0.91-0.98), PPIs (1.66, 1.18-2.30), and the interaction of age (<60)*PPIs (1.58, 1.13-2.19). However, diuretics were not significantly associated with hypomagnesemia. Our results suggest that serum magnesium levels should be measured regularly regardless of the duration of PPI use, especially in patients with male sex, age < 60, or low BMI. These findings will assist health professionals in the adequate use of PPIs. These findings need to be evaluated by cohort studies and long-term clinical investigations.
引用
收藏
页码:243 / 247
页数:5
相关论文
共 50 条
  • [31] The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade
    Masami Tsuchiya
    Taku Obara
    Makoto Miyazaki
    Aoi Noda
    Chizuko Takamura
    Nariyasu Mano
    International Journal of Clinical Pharmacy, 2020, 42 : 728 - 736
  • [32] The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade
    Tsuchiya, Masami
    Obara, Taku
    Miyazaki, Makoto
    Noda, Aoi
    Takamura, Chizuko
    Mano, Nariyasu
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (02) : 728 - 736
  • [33] Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases
    Shimada, Kazuyo
    Hasegawa, Shiori
    Nakao, Satoshi
    Mukai, Ririka
    Matsumoto, Kiyoka
    Tanaka, Mizuki
    Uranishi, Hiroaki
    Masuta, Mayuko
    Nishida, Shohei
    Shimizu, Shinya
    Hayashi, Yuichi
    Nakamura, Mitsuhiro
    Suzuki, Akio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (05) : 1097 - 1105
  • [34] Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases
    Kazuyo Shimada
    Shiori Hasegawa
    Satoshi Nakao
    Ririka Mukai
    Kiyoka Matsumoto
    Mizuki Tanaka
    Hiroaki Uranishi
    Mayuko Masuta
    Shohei Nishida
    Shinya Shimizu
    Yuichi Hayashi
    Akio Suzuki
    Mitsuhiro Nakamura
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1097 - 1105
  • [35] Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database
    Noda, Aoi
    Sakai, Takamasa
    Obara, Taku
    Miyazaki, Makoto
    Tsuchiya, Masami
    Oyanagi, Gen
    Murai, Yuriko
    Mano, Nariyasu
    BMC PHARMACOLOGY & TOXICOLOGY, 2020, 21 (01):
  • [36] Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database
    Aoi Noda
    Takamasa Sakai
    Taku Obara
    Makoto Miyazaki
    Masami Tsuchiya
    Gen Oyanagi
    Yuriko Murai
    Nariyasu Mano
    BMC Pharmacology and Toxicology, 21
  • [37] Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database
    Uwai, Y.
    Nabekura, I
    PHARMAZIE, 2022, 77 (7-9): : 255 - 261
  • [38] Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
    Shotaro Kobayashi
    Norio Sugama
    Hiroyuki Nagano
    Ayaka Miyamori
    Masahiro Takahashi
    Akifumi Kushiyama
    Drugs - Real World Outcomes, 2023, 10 : 321 - 329
  • [39] Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
    Kobayashi, Shotaro
    Sugama, Norio
    Nagano, Hiroyuki
    Miyamori, Ayaka
    Takahashi, Masahiro
    Kushiyama, Akifumi
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 321 - 329
  • [40] Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database
    Hasegawa, Shiori
    Matsui, Toshinobu
    Hane, Yuuki
    Abe, Junko
    Hatahira, Haruna
    Motooka, Yumi
    Sasaoka, Sayaka
    Fukuda, Akiho
    Naganuma, Misa
    Hirade, Kouseki
    Takahashi, Yukiko
    Kinosada, Yasutomi
    Nakamura, Mitsuhiro
    PLOS ONE, 2017, 12 (07):